About: Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America
Creator	Chb, Attia, Rizwan Bloom, Jordan Crowley, Jerome D'alessandro, David Funamoto, Masaki Hibbert, Kathryn Moonsamy, Philicia Onwugbufor, Michael Osho, Asishana Raz, Yuval Shelton, Kenneth Sundt, Thoralf Trahanas, John Villavicencio, Mauricio
source	Medline; PMC
abstract	SUMMARY AND BACKGROUND DATA: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. METHODS: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. RESULTS: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43–53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4–18 days). CONCLUSIONS: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1097/sla.0000000000004084
bibo:pmid	32675503
has license	no-cc
sha1sum (hex)	caedcb21777773bc1efa176dd8e0a971df4b9df1
schema:url	https://doi.org/10.1097/sla.0000000000004084
resource representing a document's title	Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America
has PubMed Central identifier	PMC7373471
has PubMed identifier	32675503
schema:publication	Ann Surg
resource representing a document's body	covid:caedcb21777773bc1efa176dd8e0a971df4b9df1#body_text
is schema:about of	named entity 'ECMO' named entity 'data' named entity 'healthcare' named entity 'infection' named entity 'ECMO' named entity 'modified' named entity 'exposing' named entity 'Patients' named entity 'CRITICAL CARE' named entity 'REPORT' named entity 'OUTCOMES' named entity 'PATIENT' named entity 'LUNG' named entity 'MALE' named entity 'HEMORRHAGIC STROKE' named entity 'patients' named entity 'describing' named entity 'program' named entity 'therapy' named entity 'patients' named entity 'hemorrhagic stroke' named entity 'outline' named entity 'patients' named entity 'Data' named entity 'therapy' named entity 'care management' named entity 'COVID' named entity 'COVID' named entity 'nitric oxide' named entity 'ECMO' named entity 'cannulation' named entity 'COVID-19' named entity 'ECMO' named entity 'Extracorporeal Membrane Oxygenation' named entity 'Academic Medical Center' named entity 'Massachusetts' named entity 'extracorporeal life support organization' named entity 'BMI' named entity 'internal jugular' named entity 'ARDS' named entity 'cannulated' named entity 'respiratory therapists' named entity 'body surface area' named entity 'Image guidance' named entity 'North America' named entity 'cannulation' named entity 'operating room' named entity 'flow rates' named entity 'catheters' named entity 'respiratory infections' named entity 'ICU' named entity 'respiratory therapists' named entity '3.5' named entity 'ventilator' named entity 'gas exchange' named entity 'ARDS' named entity 'cannula' named entity 'lungs' named entity 'internal jugular vein' named entity 'Body mass index' named entity 'COVID' named entity 'relative contraindication' named entity 'mechanical ventilation' named entity 'ECMO' named entity 'decannulation' named entity 'H1N1' named entity 'medical centers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software